Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. (RLAY) on December 9, 2021, reporting events occurring on December 8, 2021. The Company is a biopharmaceutical firm incorporated in Delaware and listed on The Nasdaq Global Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of a director:
- Resignation: Dipchand (Deep) Nishar tendered his resignation as a Class III director of the Board, effective December 8, 2021.
- Reason: The resignation was not the result of any dispute or disagreement with the Company, management, or the Board regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, or specific risk factors beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Mr. Nishar's resignation.
- Confirm whether a replacement director has been appointed or if the seat remains vacant.
- Review subsequent filings for any impact on corporate governance or strategic direction.